Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer

Published:1992-01 Issue:3 Volume:24 Page:573-574
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Trovo Mauro G.,Zanelli Giuseppe D.,Minatel Emilio,Franchain Giovanni,Gobitti Carlo

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference3 articles.

1. Is concomitant cisplatin and radiotherapy more efficacious treatment than radiotherapy alone in Stage III non-small cell lung cancer?;Komaki;Int. J. Rad. Oncol. Biol. Phys.,1992

2. The uptake of 3H-Vincristine by a mouse carcinoma during a course of fractionated radiotherapy;Zanelli;Br. J. Cancer,1989

3. The effect of timing of Vincristine administration during a course of fractionated radiotherapy in a mouse carcinoma;Zanelli;Eur. J. Cancer,1992

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer;BMC Cancer;2022-06-20

2. ACR Appropriateness Criteria Nonsurgical Treatment for Non–Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent;Journal of the American College of Radiology;2013-09

3. Treatment of Stage III Non-small Cell Lung Cancer;Chest;2013-05

4. Stage III vs. stage IV lung cancer: “Crossing a Great Divide”;Lung Cancer;2010-01

5. ACR Appropriateness Criteria® on Nonsurgical Treatment for Non–Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent;Journal of the American College of Radiology;2009-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3